| 000 | 01734 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515000309.0 | ||
| 264 | 0 | _c20051019 | |
| 008 | 200510s 0 0 eng d | ||
| 022 | _a0146-6615 | ||
| 024 | 7 |
_a10.1002/jmv.20452 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPellegrin, Isabelle | |
| 245 | 0 | 0 |
_aCan highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. _h[electronic resource] |
| 260 |
_bJournal of medical virology _cOct 2005 |
||
| 300 |
_a164-72 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 | _aAntiretroviral Therapy, Highly Active |
| 650 | 0 | 4 | _aCD4 Lymphocyte Count |
| 650 | 0 | 4 |
_aDNA, Viral _xblood |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Resistance, Multiple, Viral |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHIV Infections _xblood |
| 650 | 0 | 4 |
_aHIV-1 _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 |
_aRNA, Viral _xblood |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aThiébaut, Rodolphe | |
| 700 | 1 | _aBlanco, Patrick | |
| 700 | 1 | _aViallard, Jean-François | |
| 700 | 1 | _aSchrive, Marie-Hélène | |
| 700 | 1 | _aMerel, Patrick | |
| 700 | 1 | _aChêne, Geneviève | |
| 700 | 1 | _aFleury, Hervé | |
| 700 | 1 | _aMoreau, Jean-François | |
| 700 | 1 | _aPellegrin, Jean-Luc | |
| 773 | 0 |
_tJournal of medical virology _gvol. 77 _gno. 2 _gp. 164-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jmv.20452 _zAvailable from publisher's website |
| 999 |
_c15758093 _d15758093 |
||